Towards Biomarker- Dependent Tailored Chemotherapy: Quantitative Analysis Of Drug- DNA Adducts Using Accelerator Mass Spectrometry | 6013
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Towards Biomarker- Dependent Tailored Chemotherapy: Quantitative Analysis of Drug- DNA Adducts Using Accelerator Mass Spectrometry

2nd International Conference on Analytical & Bioanalytical Techniques

Sang Soo Hah

ScientificTracks Abstracts: J Anal Bioanal Techniques

DOI: 10.4172/2155-9872.S1.02

The use of radioisotopes has a long history in biomedical science, and the technique of accelerator mass spectrometry (AMS), an extremely sensitive nuclear physics technique for detection of very low-abundant, stable and long-lived isotopes, has now revolutionized high-sensitivity isotope detection in biomedical research, because it allows the direct determination of the amount of isotope in a sample rather than measuring its decay, and thus the quantitative analysis of the fate of the radiolabeled probes under the given conditions. Since AMS was fi rst used in the early 90�s for the analysis of biological samples containing enriched 14 C for toxicology and cancer research, the biomedical applications of AMS to date range from in vitro to in vivo studies. In this talk, I will present successful AMS applications to measurement of the kinetics and repair of DNA adducts formed by two chemotherapeutic compounds, carboplatin and oxaliplatin. Ultimately, I hope to use this method to measure the intrinsic platinated DNA adduct repair capacity in cancer patients for use as a biomarker for diagnostics or a predictor of patient outcome.

Sang Soo Hah received his Ph.D. in Bioorganic Chemistry from the College of Natural Sciences at Seoul National University, and worked as a Postdoctoral Fellow at Columbia University, USA, and at Lawrence Livermore National Laboratory, USA, in order to extend his research experience to the areas of molecular biology and toxicology, and of cancer etiology and pharmacology. He also worked in industry as a Research Fellow. He is an Assistant Professor (Department of Chemistry) and Director (Research Center for New Nano Bio Fusion Technology) at Kyung Hee University, South Korea.